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Abstract
The Stanley Foundation Bipolar Network (SFBN) is an
international, multisite network investigating the charac-
teristics and course of bipolar disorder. Methods (histo-
ry, ratings and longitudinal follow-up) are standardized
and equally applied in all 7 centres. This article describes
demographics and illness characteristics of the first 152
German patients enrolled in the SFBN as well as the
results of 2.5 years of follow-up. Patients in Germany
were usually enrolled after hospitalisation. More than
72% of the study population suffered from bipolar I dis-
order and 25% from bipolar II disorder. The mean B SD
age of the study participants was 42.08 B 13.5 years, and
the mean B SD age of onset 24.44 B 10.9 years. More
than 40% of the sample reported a rapid-cycling course
in history, and even more a cycle acceleration over time.
37% attempted suicide at least once. 36% had an addi-
tional Axis I disorder, with alcohol abuse being the most
common one, followed by anxiety disorders. During the
follow-up period, only 27% remained stable, 56% had a
recurrence, 12.8% perceived subsyndromal symptoms
despite treatment and regular visits. 27% suffered from a
rapid-cycling course during the follow-up period. Recur-
rences were significantly associated with bipolar I disor-
der, an additional comorbid Axis I disorder, rapid cycling
in history, a higher number of mood stabilizers and the
long-term use of typical antipsychotics. Rapid cycling
during follow-up was only associated with a rapid-
cycling course in history, a higher number of mood stabi-
lizers and at least one suicide attempt in history.
Copyright © 2003 S. Karger AG, Basel
Introduction
Bipolar disorder is a common, severe and persistent
illness with a prevalence rate of 1.3–1.7% [1, 2]. Accord-
ing to some authors who also include bipolar spectrum
disorders, the prevalence rate increases to 3–7% [3–6].
Taking this into account, bipolar illness affects at least 1
million people in Germany, about 4 million in the USA
and 3.2 million people in Europe. Even though research
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efforts have been reinforced lately, many questions still
remain open concerning the course, treatment and origins
of this devastating illness. In 1989 and 1994, the National
Institute of Mental Health organized two bipolar disorder
workshops which concluded that there is still an enor-
mous need for research on bipolar illness [7, 8]. Especially
the need for controlled clinical treatment trials for bipolar
depression and maintenance treatment was emphasized.
Furthermore, the two workshops recommended the de-
velopment of a consortium of academic centres, patient
advocacy groups and the pharmaceutical industry to in-
crease the number and representativeness of patients in
controlled clinical trials and to help develop methods and
assessment devices that would accurately describe the ill-
ness course [9]. As a result, the Stanley Foundation Bipo-
lar Network (SFBN) was established with the generous
support of Vada and Theodore Stanley in order to im-
prove research for bipolar affective disorders. A detailed
description of the SFBN, its rationale and the methods
used is published elsewhere [10–12]. In brief, the aim of
the Network is to enroll a large number of bipolar patients
for longitudinal studies. Patients are seen at least once a
month and psychopathology is assessed using well-known,
validated rating scales and prospective life chart method-
ology [13]. Depending on the course of the illness, patients
are offered to participate in randomized open or double-
blind clinical trials. Patients not eligible or willing to par-
ticipate in clinical treatment trials are followed up in the
Naturalistic Follow-up Study (NFS). Treatment of these
patients is not restricted, but up to the clinician’s choice.
The results of the NFS of the two German centres after 2.5
years of follow-up are presented in this paper.
Methodology
Until 1998, the Network had been composed of four University
Hospitals in the USA (Bethesda, Los Angeles, Dallas and Cincinnati)
and one in The Netherlands (Utrecht). In 1999, the Psychiatric Hos-
pitals of the Universities of Munich and Freiburg, Germany joined
the SFBN as affiliated sites. In Germany, patients recruited to the
study were usually enrolled after hospitalisation or by self-referral.
All patients provided written informed consent prior to entering the
network. The inclusion criteria for entry were the diagnosis of bipolar
disorder (I, II, NOS) or schizoaffective disorder (bipolar type)
according to DSM-IV, age older than 18 years and the willingness to
return for monthly follow-up visits. Comorbid psychiatric or medical
illnesses were no exclusion criteria, except any substance abuse
requiring acute treatment.
At entry, the diagnosis and other Axis I disorders were confirmed
using the Structured Clinical Interview of DSM-IV [14]. Demograph-
ic and clinical variables were assessed using questionnaires com-
pleted by clinicians and patients [9]. Axis II disorders (Personality
Disorder Questionnaire [15]), depressive [Inventory of Depressive
Symptoms [16] (IDS)], manic [Young Mania Rating Scale [17]
(YMRS)] and psychotic symptomatology [Positive and Negative
Syndrome Scale [18] (PANSS)], overall mood [Clinical Global Im-
pressions Scale for Bipolar Illness [19] (CGI-BP)] and global func-
tioning [Global Assessment of Functioning Scale [20] (GAF)] were
assessed as well. The course of the illness was assessed using the retro-
spective and prospective Life-Chart Methodology (LCM) [13].
Patients were usually followed up monthly, but when clinically
indicated, also more often. At every follow-up visit, the same psycho-
metric scales were applied again (IDS, YMRS, CGI-BP, GAF, LCM)
to assess symptomatology, the course of illness and treatment.
Patients had the choice to receive their medical care entirely at
the Stanley Research Clinics or to visit a psychiatrist in a private
practice. Treatment in the NFS was not standardized, but was up to
the treating psychiatrist’s choice depending on the course of the ill-
ness.
Statistical analyses were performed using the Statistical Products
for Service Solutions version 10.1. Frequencies were run on demo-
graphic and clinical variables as well as treatment characteristics.
Fisher’s exact test was used to test significance for categorical, Stu-
dent’s t test was used to evaluate continuous variables. Statistical sig-
nificance was set at 0.05 (two-tailed).
Results
More than 700 patients with bipolar or schizoaffective
disorders have been enrolled in the whole Network so far
[9]. In Germany, 152 patients have been enrolled consec-
utively since 1999 and have been followed up prospec-
tively for an average of 13.13 months (1–32 months).
Clinical and Demographic Variables of the Sample
Table 1 shows the most important demographic and
clinical variables of the 152 patients enrolled in Germany.
Most patients suffer from a bipolar I disorder (72.1%),
followed by patients with bipolar II disorder (25.2%).
Only few patients with a bipolar disorder NOS or schi-
zoaffective disorder participated in the study (0.7 and 2%,
respectively). The distribution of age and sex is compara-
ble with other cohort studies of bipolar patients [9, 21].
Almost 60% of the patients lived on their own, either in
an apartment or in sheltered housing. Only 40% lived
together with their partners or families. This is also in line
with other studies [22]. While in many epidemiologic
studies most bipolar patients also suffer from comorbid
Axis I disorders, above all substance abuse and anxiety
disorders, in our sample, only 35.8% of the patients had
had an additional Axis I disorder during their lifetime, of
which substance abuse was the most common one
(26.3%), followed by anxiety disorders (12.5%). Only few
patients also suffered from an eating disorder (7.2%).
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Table 1. Demographic and clinical variables
Whole sample
(n = 152)
Bipolar I
(n = 108)
Bipolar II
(n = 38)
Current age, years 42.08B13.5 (21–80) 40.95B12.62 45.89B15.10
Gender, %
Female
Male
51.7
48.3
50.9
49.1
50.0
50.0
Marital status, %
Married/cohabitation
Widowed
Divorced/separated
Single
40.4
2.1
15.7
41.8
37.4
1.9
14.1
46.2
44.7
7.9
21.1
26.3
Current living situation, %
With spouse/partner
Single parent
Single
With family of origin
In group home
Other
40.4
2.1
46.4
8.2
1.4
1.4
36.8
0.9
49.1
9.4
1.9
1.9
47.4
5.3
44.7
2.6
0
0
Diagnosis, %
Bipolar I
Bipolar II
Bipolar NOS
Schizoaffective disorder
72.1
25.2
0.7
2.0
Age of onset, years 24.44B10.9 (9–63) 23.97B11.2 (13–63) 25.82B10.5 (9–50)
Age at first treatment
Age at first hospitalisation
29.77B10.6
31.11B13.2
29.65B11.5
30.45B12.2
29.94B9.3
31.57B13.7
Comorbid Axis I disorders, % 35.8 35.9 37.8
Any substance abuse 26.3 25.5 28.9
Alcohol abuse 17.8 18.9 18.4
Substance abuse (without alcohol) 8.5 6.6 10.5
Any anxiety disorder 12.5 10.4 18.4
Any eating disorder 7.2 9.4 0
Table 2 shows the distribution of the socioeconomic
status of the sample. Even though many patients were
highly educated (28.3% finished university or a compara-
ble education), only one third of the sample was able to
work full-time in jobs which matched their qualifications.
Most of the patients were unable to work (13.5%), retired
(26.6%) unemployed (7.8%) or in rehabilitation programs
(3.5%). The limitation of the occupational functioning is
also obvious from household income. One third of the
bipolar patients has to live with less than 10,000 EUR/
year, more than half of the sample with less than 20,000
EUR/year.
When asked for their own judgement, more than two
thirds (61.4%) of the patients feel that their occupational
functioning is limited moderately to severely due to their
bipolar illness even in free intervals.
Important illness characteristics are shown in table 3.
Almost 41% of the patients reported a history of rapid
cycling. No significant differences were found between
the diagnostic groups (data not shown). Almost 14% of
the sample suffered from ultradian cycling which was
defined as cycling within a day. Almost half of the sample
(44.7%) reported a worsening of their illness over time
due to cycle acceleration, a substantial number of patients
additionally reported an increase in severity. These find-
ings are also in line with other studies [9, 22]. There is a
big difference between the number of episodes and hospi-
talizations. While the vast majority of patients (83.4%)
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Table 2. Socioeconomic status
Whole sample Bipolar I Bipolar II
(n = 152) (n = 108) (n = 38)
Employment status, %
Full-time
Equal to qualifications 29.6 26.4 34.2
In household 2.8 2.9 5.3
Below qualifications 2.8 2.9 2.6
Part-time 7.8 5.9 10.5
Unemployed 7.8 5.9 13.2
Rehabilitation program/sheltered workshop 3.5 4.9 0.0
Unable to work 13.5 17.6 2.6
Retired/disability pension 26.6 27.5 23.7
Other 6.4 5.9 7.9
Education, %
Hauptschulabschluss (10 years) 8.1 5.7 10.5
Mittlere Reife (High school) 8.7 10.4 5.3
Abitur (13 years) 26.2 31.1 13.2
Apprenticeship 28.9 26.4 36.8
University 22.9 12.6 23.7
Graduation 5.4 3.8 10.5
Household income in DM, %
!20,000 30.6 32.4 24.3
20,000–39,999 25.9 29.5 16.2
40,000–59,999 13.6 14.3 10.8
60,000–79,999 12.9 9.5 21.6
80,000–99,999 6.1 4.8 10.8
100,000+ 9.5 7.6 16.2
Occupational functioning limited by bipolar illness (free interval), %
Not limited 0.8 1.1 0
Mildly 37.8 36.6 38.9
Moderately 23.6 24.7 25.0
Markedly 15.0 17.2 11.1
Severely 12.6 10.8 11.1
No free interval 10.2 9.7 13.9
have suffered from at least 5 episodes in their lives, only
half of the patients have been hospitalized as often as that.
The difference is even clearer in patients which have suf-
fered from more than 20 episodes. While almost 40% of
the sample say they have had at least 20 episodes in their
lifetime, only 9.2% have also been hospitalized as often as
that. There was no statistical difference between the two
major diagnostic groups (data not shown).
Results of the Follow-Up Period
During the prospective observation period, only 27%
of all patients remained free of symptoms. The majority
of patients (56%) suffered from at least one recurrence.
12.8% of the patients perceived subsyndromal symptoms
not long or severe enough to fulfil the diagnostic criteria
for a recurrence. That means a vast majority of the sample
(68.8%) suffered from mood disturbances despite treat-
ment adherence and regular visits to a professional. About
a quarter of the study population suffered from a rapid-
cycling course during follow-up (26.5%). The treatment of
111 patients of the sample could be analysed more pre-
cisely. Of this subsample, almost all (97.3%) were on at
least 1 mood stabilizer during follow-up. Most of the
patients were on just 1 mood stabilizer (60.4%), about one
third of the sample (33.3%) had a combination treatment
of 2 mood stabilizers, and the remaining patients were on
either 3 or 4 mood stabilizers (2.7 and 0.9%, respectively).
Even though there is a wide range of treatment options
now, the most important mood stabilizer is still lithium.
Almost one quarter of our sample (23.1%) were on lithi-
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Table 3. Illness characteristics
Whole sample Bipolar I Bipolar II
(n = 141) (n = 107) (n = 36)
History of rapid cycling, % 40.7 39.8 41.2
No rapid cycling 59.3 60.2 58.8
Rapid cycling 16.8 14.0 20.6
Ultra-rapid cycling 9.9 11.8 5.9
Ultradian cycling 13.7 14.0 14.7
Number of episodes, %
1–4 16.5 14.6 20.6
5–10 26.3 24.0 32.4
11–20 17.3 19.8 11.8
20+ 39.8 41.7 35.3
Hospitalizations, %
0–4 54.6 53.5 54.8
5–10 26.1 25.6 29.0
11–20 10.1 9.3 12.9
20+ 9.2 11.6 3.2
Cycle acceleration, % 44.7 44.4 38.9
More severe episodes of depression 55.1 51.0 66.7
More severe episodes of hypomania 34.4 35.7 35.3
More severe episodes of mania 38.6 41.2 0
History of suicide attempts, %
None 63.4 62.8 63.9
At least 1 36.6 37.2 36.1
More than 4 7.5 8.5 5.6
Interepisode symptoms, %
No symptoms 42.0 42.4 42.9
Mild symptoms 38.9 37.0 42.9
Significant symptoms 4.6 4.3 2.9
Substantial symptoms 2.3 3.3 0
Cycle continuously 12.2 13.0 11.4
Feeling of stigmatization, %
Not at all 31.7 29.2 37.1
Mild 26.8 27.0 25.7
Moderate 30.1 33.7 25.7
Severe 11.4 10.1 11.4
um alone, another 21.2% on a combination treatment of
lithium and another mood stabilizer (e.g. valproate or car-
bamazepine). An increasing number of patients is also on
a combination treatment of lithium and an atypical anti-
psychotic (4.6%). Valproate alone or in combination with
another mood stabilizer was the treatment of choice in
30.3% of the study population. Interestingly, there is still
a high proportion of patients who also get a long-term
treatment with antidepressants or typical antipsychotics
(for at least 6 months, 42.3 and 24.5%, respectively). Dur-
ing the observation period, 50 patients (33%) dropped out
for various reasons.
Recurrences
About 56% of the patients suffered from at least one
recurrence in the follow-up period. Patients with a bipolar
I disorder significantly more often had a recurrence than
patients with a bipolar II disorder (p ! 0.044). Further-
more, patients with an additional comorbid Axis I disor-
der or a rapid-cycling course in history also suffered more
often from a recurrence than patients without any (p !
0.047 and p ! 0.005, respectively). However, there is also
another significant difference: patients who had a recur-
rence during the follow-up period were on significantly
more mood stabilizers and more often on an additional
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Table 4. Recurrence during follow-up
Recurrence No recurrence p value
Age1 43.18B13.50 39.32B11.43 0.081
Age of onset1 24.12B11.66 25.85B9.31 0.351
Gender: female2 39 (50) 33 (55) 0.608
Bipolar I2 62 (82) 37 (65) 0.044*
Any comorbid Axis I disorder2 34 (43) 15 (25) 0.047*
Substance abuse2 25 (32) 12 (19) 0.124
Anxiety disorder2 12 (15) 5 (8) 0.297
Eating disorder2 7 (9) 4 (6) 0.755
Rapid cycling in history2 37 (56) 15 (29) 0.005*
Suicide attempt in history2 22 (39) 14 (29) 0.309
Living situation (alone)2 45 (58) 31 (56) 1.0
Number of mood stabilizers1 1.52B0.72 1.26B0.49 0.033*
Use of antidepressants2, 3 27 (45) 17 (37) 0.433
Use of antipsychotics2, 3 21 (36) 5 (11) 0.006*
Figures in parentheses are percent values.
1 T test.
2 Fisher’s exact test.
3 More than 6 months during follow-up.
Table 5. Rapid cycling during follow-up
Rapid cycling No rapid cycling p value
Age1 41.79B11.35 41.62B13.44 0.943
Age of onset1 31.5B13.99 26.18B10.19 0.085
Female2 19 (49) 57 (53) 0.711
Bipolar I2 27 (71) 80 (76) 1.0
Comorbid axis I disorder2 12 (31) 39 (38) 0.558
Substance abuse2 11 (28) 27 (25) 1.0
Anxiety disorder2 7 (18) 11 (10) 1.0
Eating disorder2 1 (3) 9 (8) 0.291
Early age of onset (0–17)2 15 (38) 16 (15) 1.0
Rapid cycling in history2 27 (75) 27 (31) 0.000*
Suicide attempt in history2 17 (59) 19 (23) 0.001*
Living situation (alone)2 24 (62) 59 (58) 1.0
Number of mood stabilizers1 1.70B0.64 1.26B0.59 0.001*
Use of antidepressants2, 3 14 (42) 33 (42) 1.0
Use of antipsychotics2, 3 10 (31) 17 (22) 1.0
Figures in parentheses are percent values.
1 T test.
2 Fisher’s exact test.
3 More than 6 months during follow-up.
typical antipsychotic than patients who remained stable
(p ! 0.033 and p ! 0.006, respectively). There were no
significant differences concerning gender, age, age of on-
set, living situation (alone vs. with family), suicide at-
tempts in history and long-term antidepressant use during
the follow-up period (table 4).
Rapid Cycling
More than a quarter of the sample (26.5%) had a rapid-
cycling course (i.e. at least 4 episodes within 12 months)
during the follow-up period. Moreover, patients who
actually suffered from rapid cycling significantly more
often had a rapid-cycling course in their history (p !
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0.000) and were on more mood stabilizers than patients
without rapid cycling (p ! 0.001). If patients had more
than 4 episodes during the follow-up period, they signifi-
cantly more often had at least one suicide attempt in his-
tory (p ! 0.001). There were no significant differences
between patients with or without a rapid-cycling course
concerning age, age of onset, gender, comorbid disorders,
alcohol or substance abuse, living situation (alone or with
family) and long-term antidepressant or antipsychotic use
during follow-up (table 5).
Discussion
In this article, the characteristics of the first 152 Ger-
man patients enrolled in the SFBN as well as some fea-
tures of the follow-up period are described. As far as the
demographic and clinical variables are concerned, there
are not many differences between our patient sample and
other clinical samples of bipolar patients [9, 21, 22]. Gen-
der, age, martial status, education and diagnosis are com-
parable with those of other studies. Like the American
SFBN study participants [9], the majority of our patients
was highly educated, but only one third was able to work
in positions which met their qualifications. More than
half of the sample worked below their qualifications, in
sheltered workshops or were unable to work and therefore
got an invalidity pension. This limitation of functioning
was reported by the patients themselves and was also
reflected by the low annual household income of less than
10,000 EUR for more than 30% of the study population.
Thus, the German SFBN study population confirms the
results of other naturalistic studies [9, 23].
The major discrepancy to other studies, however, is the
difference in comorbid psychiatric disorders. While many
studies describe a proportion of up to 50% of bipolar
patients with an additional substance abuse [2, 24–26]
and up to a 93% frequency of lifetime anxiety disorders in
bipolar I patients [27], in our study, only 35.8% had an
additional Axis I disorder. Like in other studies, alcohol
abuse was the most frequent one (17.8%) followed by anx-
iety disorders (12.5%). The reason for such a low rate is
not quite sure. A selection bias may be possible. With
bipolar disorder often unrecognized, many patients may
seek care in a setting specialized in their comorbid disor-
der. Additionally, most reports on high comorbidity rates
are based on US populations which may not be compara-
ble with conditions in Germany.
More than 40% of the patients report a rapid-cycling
course in history, and almost 27% had 4 or more episodes
during the 2.5 years of follow-up. While other studies
describe different predictors for rapid cycling such as age,
age of onset, female sex, bipolar II disorder or antidepres-
sant use [28], our study could not confirm these results.
There was only an association between rapid cycling and
suicide attempts, rapid cycling in history and a higher
number of mood stabilizers. These associations are not
surprising. It is rather obvious that a single mood stabi-
lizer is often not enough to prevent new episodes, the
more severe the disorder is.
Concerning treatment, it has to be stated that despite
our elaborated setting and state-of-the-art treatment,
more than half of the patients experienced a relapse dur-
ing follow-up. Patients with bipolar I disorder or a comor-
bid Axis I disorder were on highest risk for relapse. It is an
obvious conclusion that we still lack a ‘golden standard’ in
treatment, especially in this high-risk population of bipo-
lar patients.
This study has a number of limitations to generalize
these data. First of all, the study population was usually
enrolled after hospitalisation in a university hospital.
That is why this sample does not represent patients in the
community but rather patients who are severely ill, which
is also reflected by the high percentage of patients who
had more than 20 episodes. Still, the major results of this
study are comparable with other studies with clinical sam-
ples. Another limitation is that patients had to be willing
to complete ratings and attend regular appointments.
Usually, patients willing to do so were not hospitalised for
their first episode, but had already been ill for several
years. On the other hand, the SFBN has a number of
strengths like standardized methodology, detailed pro-
spective ratings of mood, sleep, life events and medica-
tion and continuous longitudinal follow-up.
Nonetheless, this study again reveals the high morbidi-
ty of this illness despite multiple treatment available and
therefore emphazises the need for research in this particu-
lar field.
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